User menu

Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions.

Bibliographic reference Baririan, Nariné ; Horsmans, Yves ; Desager, Jean-Pierre ; Verbeeck, Roger-K. ; Vanbinst, Roger ; et. al. Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions.. In: Journal of clinical pharmacology, Vol. 45, no. 12, p. 1434-41 (2005)
Permanent URL http://hdl.handle.net/2078.1/25644
  1. Walsky R. L., VALIDATED ASSAYS FOR HUMAN CYTOCHROME P450 ACTIVITIES, 10.1124/dmd.32.6.647
  2. Donato M. Teresa, Castell Jos?? V., Strategies and Molecular Probes to Investigate the Role of Cytochrome P450 in Drug Metabolism : Focus On In Vitro Studies, 10.2165/00003088-200342020-00004
  3. Gibbs Megan A, Hosea Natilie A, Factors Affecting the Clinical Development of Cytochrome P450 3A Substrates : , 10.2165/00003088-200342110-00003
  4. Brockmöller Jürgen, Roots Ivar, Assessment of Liver Metabolic Function : Clinical Implications, 10.2165/00003088-199427030-00005
  5. Watkins Paul B., Noninvasive tests of CYP3A enzymes : , 10.1097/00008571-199408000-00001
  6. Kivistö Kari T., Kroemer Heyo K., Use of Probe Drugs as Predictors of Drug Metabolism in Humans, 10.1177/009127009703700121
  7. Streetman Daniel S., Bertino Joseph S., Nafziger Anne N., Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes : , 10.1097/00008571-200004000-00001
  8. KRECICSHEPARD M, BARNAS C, SLIMKO J, GORSKI J, WAINER I, SCHWARTZ J, In vivo comparison of putative probes of CYP3A4/5 activity: Erythromycin, dextromethorphan, and verapamil, 10.1016/s0009-9236(99)70052-4
  9. Fleming, Mol Pharmacol, 41, 975 (1992)
  10. Wang, Drug Metab Dispos, 28, 959 (2000)
  11. Kinirons Mark T, O'Shea Diarmuid, Downing Trisha E, Fitzwilliam Ailsa T, Joellenbeck Lois, Groopman John D, Wilkinson Grant R, Wood Alastair J J, Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men, 10.1038/clpt.1993.199
  12. Kinirons Mark T., O'Shea Diarmuid, Kim Richard B., Groopman John D., Thummel Kenneth E., Wood Alastair J. J., Wilkinson Grant R., Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A*, 10.1016/s0009-9236(99)70029-9
  13. Krivoruk Yuri, Kinirons Mark T, Wood Alastair J J, Wood Margaret, Metabolism of cytochrome P4503A substrates in vivo administered by the same route: Lack of correlation between alfentanil clearance and erythromycin breath test, 10.1038/clpt.1994.185
  14. Kharasch Evan D., Russell Michael, Mautz Douglas, Thummel Kenneth E., Kunze Kent L., Bowdle T. Andrew, Cox Kathy, The Role of Cytochrome P450 3A4 in Alfentanil Clearance : Implications for Interindividual Variability in Disposition and Perioperative Drug Interactions, 10.1097/00000542-199707000-00006
  15. Labroo, Drug Metab Dispos, 23, 490 (1995)
  16. Klees Theresa Mariero, Sheffels Pamela, Thummel Kenneth E., Kharasch Evan D., Pharmacogenetic Determinants of Human Liver Microsomal Alfentanil Metabolism and the Role of Cytochrome P450 3A5 : , 10.1097/00000542-200503000-00012
  17. Klees T. M., METABOLISM OF ALFENTANIL BY CYTOCHROME P4503A (CYP3A) ENZYMES, 10.1124/dmd.104.002709
  18. Lin, Pharmacol Rev, 51, 135 (1999)
  19. Chauvin M., Bonnet F., Montembault C., Levron J. C., Viars P., The Influence of Hepatic Plasma Flow on Alfentanil Plasma Concentration Plateaus Achieved with an Infusion Model in Humans : Measurement of Alfentanil Hepatic Extraction Coefficient, 10.1213/00000539-198610000-00001
  20. Kharasch Evan D., Russell Michael, Garton Kyle, Lentz Gretchen, Bowdle T. Andrew, Cox Kathy, Assessment of Cytochrome P450 3A4 Activity during the Menstrual Cycle Using Alfentanil as a Noninvasive Probe : , 10.1097/00000542-199707000-00005
  21. MILLER C. D., ASBURY A. J., BROWN J. H., PUPILLARY EFFECTS OF ALFENTANIL AND MORPHINE, 10.1093/bja/65.3.415
  22. Pickworth, Methods Find Exp Clin Pharmacol, 11, 759 (1989)
  23. Phimmasone S, A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans, 10.1067/mcp.2001.119994
  24. KHARASCH E, WALKER A, HOFFER C, SHEFFELS P, Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: Noninvasive assessment by use of pupillary miosis, 10.1016/j.clpt.2004.07.006
  25. Kharasch E, Disposition and miotic effects of oral alfentanil: A potential noninvasive probe for first-pass cytochrome P4503A activity, 10.1067/mcp.2003.30
  26. Mautz Douglas S., Labroo Rita, Kharasch Evan D., Determination of alfentanil and noralfentanil in human plasma by gas chromatography—mass spectrometry, 10.1016/0378-4347(94)00201-0
  27. Gabrielsson, Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications (2005)
  28. BOWER SUSANNE, HULL C. J., COMPARATIVE PHARMACOKINETICS OF FENTANYL AND ALFENTANIL, 10.1093/bja/54.8.871
  29. Kharasch Evan D., Thummel Kenneth E., Human Alfentanil Metabolism by Cytochrome P450 3A3/4. An Explanation for the Interindividual Variability in Alfentanil Clearance? : , 10.1213/00000539-199305000-00022
  30. Piafsky K. M., Disease-induced Changes in the Plasma Binding of Basic Drugs : , 10.2165/00003088-198005030-00004